T1	Participants 50 119	hyperglycemic patients with non-ST elevation acute coronary syndrome.
T2	Participants 285 431	patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study.
T3	Participants 691 761	patients with diabetes and A1C of >or=8-10% at randomization (n = 171)
T4	Participants 862 888	placebo-adjusted (n = 182)
T5	Participants 968 1041	patients with FPG of 150-400 mg/dl at randomization, ranolazine (n = 131)
T6	Participants 1056 1073	placebo (n = 147)
T7	Participants 1709 1777	patients with cardiovascular disease and poorly controlled diabetes.
